At the end of the day, I think that would be a policy decision that governments would have to make, and we would also have to consult with the provincial and territorial governments.
When we looked at the particular regulation that was out for discussion last year, one of the concerns was exactly this issue of the balloon effect. The other thing was that most provincial formularies had taken generic oxycodone off of their formularies. It's the tamper-proof version that they make available, but there are a number of Canadians who, for financial or other reasons, may not be able to afford that kind of medicine. You have to realize that the tamper-proof formulation is two to four times more expensive. If you move an entire class of pain medication into that kind of technology, you would effectively be dramatically raising the cost of—